Abstract
Clostridium difficile infection is increasing in incidence, severity, and mortality. Treatment options are limited and appear to be losing efficacy. Recurrent disease is especially challenging; extended treatment with oral vancomycin is becoming increasingly common but is expensive. Fecal microbiota transplantation is safe, inexpensive, and effective; according to case and small series reports, about 90% of patients are cured. We discuss the rationale, methods, and use of fecal microbiota transplantation.
Original language | English (US) |
---|---|
Pages (from-to) | 1044-1049 |
Number of pages | 6 |
Journal | Clinical Gastroenterology and Hepatology |
Volume | 9 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2011 |
Bibliographical note
Funding Information:Conflicts of interest These authors disclose the following: Thomas Borody has patents in the field of fecal transplantation. Alexander Khoruts receives funding from the Minnesota Medical Foundation and NIH grant 1R21AI091907 . The remaining authors disclose no conflicts.
Keywords
- Clostridium difficile
- Diarrhea
- Fecal Enema
- Microbiota
- Recurrent Infection
- Transplantation